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EXPANSION OF TELEDERMATOLOGY
DURING COVID-19
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Prior to COVID-19, teledermatology was
limited due to limited insurance
reimbursement for telemedicine visits,
concern about liabilities, and licensing
restrictions.
COVID-19 prompted regulatory and policy
changes, with corresponding new
telemedicine growth and innovation; health
systems created and adapted protocols to
continue care, save personal protective
equipment, and decrease unnecessary
exposures.
Teledermatology has been conducive to
COVID-19 constraints, but limitations focus
on access; dependence on telemedicine
may actually worsen care for many patients
who lack digital access.
Expansion of telemedicine reimbursements
favored synchronous video visits rather
than store-and-forward teledermatology,
which may be a missed opportunity for
more efﬁcient delivery of care.
Policy changes established during
COVID-19, though possibly temporary,
have nevertheless set new precedents that
will surely have long-term impacts on
teledermatology use post-pandemic.

A study of 168 patients found the most popular reasons for
telehealth appointments to be new rash (12%), eczema
(10%), and psoriasis (9%). A study of 153 U.S. dermatology
practices operating during the pandemic found that 87% of
practices offered teledermatology as an option to patients.
Across 12 dermatology clinics afﬁliated with Massachusetts
General Hospital, virtual visits rose from 0 in April 2019 to
1,564 in April 2020, while in-person visits for April 2020
represented less than 1% of the in-person visit volume from
the year prior. Before March 11, 2020, when the WHO
ofﬁcially declared the COVID-19 pandemic, skin conditions
were not listed among the most common telehealth
diagnoses in the United States. However, by April 2020,
skin conditions were ranked the ﬁfth most common
telehealth diagnosis in the U.S. Similarly, as of July 21,
2020, 13 of the top 50 ranked medical applications in the
U.S. Apple App Store were usable for telemedicine, an
increase of mean of 210.92 ranked positions from January
1, 2020.

LESSONS LEARNED DURING
COVID-19
Teledermatology’s efﬁcacy may vary in different
populations. The elderly may require assistance using
digital devices. We must also consider the emerging
American population whose ﬁrst language is not English.
Additional services could provide caregivers for the elderly
and translators for non-English speakers to improve
adaptation.

THE DIGITAL DIVIDE
Area of
Concern

Suggestions for Improvement

Financial
Assistance

Financial waivers could mitigate cost of
devices and internet access

Interpretation
Services

Modeled after interpretation services
used in patient, can increase quality of
communication during the visit.

Community
Based
Interventions

Community based Teledermatology
programs can serve as an adjunct to
assist with ease of use

CONCLUSIONS
In the long-term, the success of teledermatology will be
dependent on federal and state policies and laws, as well as
payers. Future policy must consider telemedicine expansion
beyond geographic restrictions and further reimbursement
increases and utilization of SAF. For sustained growth,
government policy makers, physicians, insurance companies,
and patient advocacy organizations must partner to create a
system to fortify telemedicine with the many challenges of
reimbursement, HIPAA compliance, and disparities in patient
access to telemedicine.

